Fundraising FoxSolas BioVentures — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule STAT3 inhibitors to treat inflammatory and proliferative diseases.
BiotechHealthtechHouston, US
David J. Tweardy(Executive Officer, Director)Josef Schoell(Executive Officer)inJoseph W. Stauffer(Executive Officer)Derek Chalmers(Executive Officer, Director)inMichael E. Lewis(Executive Officer)inFrederique Menzaghi(Executive Officer)
Co-investorsShangBay Capital LLC
Francis Medical is a medical device company developing minimally invasive urological cancer treatments using water vapor ablation technology, initially focused on prostate cancer with its Vanquish Water Vapor Ablation System.
BiotechDigital HealthHealthtechMedical DevicesMaple Grove, US
Michael Hoey(Founder)inMichael Kujak(Executive Officer, Director)Christopher Dixon(Chief Medical Officer)in
BoardAndrew Cleeland(Director)Jan Garfinkle(Director)inDavid Adair(Director)in
Board seatMichael Hoey· per SEC Form D
Co-investorsArboretum Ventures
Cryosa develops an incisionless medical treatment that uses controlled cooling to reduce tissue and open airways.
BiotechHealthtechMedical DevicesArden Hills, US
Laura Stoltenberg(Executive Officer, Director)in
BoardDavid Belitz(Director)inDoug French(Director)James Eadie(Director)Donald Gonzales(Founder and Chief Medical Officer)
Co-investorsBrightstone Venture Capital
Intershunt develops the Dynama System (also known as the PAS-C System), an investigational interatrial shunting device designed to create a pathway in the heart's upper chambers to reduce elevated left atrial pressure and relieve heart failure symptoms.
HardwareHealthtechMedical DevicesFridley, US
Harlan Lee Sorkin(Executive Officer, Director)Gil M. Vardi(Director)
BoardDenis Harrington(Director)inDavid Adair(Director)inJim Bullock(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Bio 54, LLC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.